SCHEMBL2927699

SCHEMBL2927699

Cc1ccc(C(=O)NC[C@H](NC(=O)c2cc(-c3ccccc3)ccn2)C(=O)NCCC(C)C)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.53
RAB9A P51151 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
CTSA P10619 2/20 0.46
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
PSMB5 P28074 2/20 0.42
PSMB8 P28062 1/20 0.42
CTSB P07858 2/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
LMNA P02545 1/20 0.41
POLB P06746 1/20 0.41
CNR1 P21554 1/20 0.41
NFKB1 P19838 1/20 0.41
NFKB2 Q00653 1/20 0.41
RELA Q04206 1/20 0.41
CTSS P25774 3/20 0.40
CTSL P07711 2/20 0.40
CTSV O60911 1/20 0.40
GRM5 P41594 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2931767 0.89 CTSA (0.46) NPC1RAB9ASMN1; SMN2CTSAPSMB5
SCHEMBL2931864 0.88 KMT2A (0.57) NPC1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL2927824 0.87 NPC1 (0.48) NPC1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL2935265 0.87 NPC1 (0.56) NPC1RAB9ASMN1; SMN2CTSAMEN1
SCHEMBL2927696 0.85 CTSA (0.44) NPC1RAB9ASMN1; SMN2CTSAMEN1
SCHEMBL2931810 0.85 NPC1 (0.45) NPC1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL2929343 0.84 PSMB5 (0.55) CTSAPSMB5PSMB8NFKB1NFKB2
SCHEMBL2935514 0.83 POLB (0.48) NPC1RAB9ASMN1; SMN2CTSAMEN1
SCHEMBL2930834 0.83 SMN1; SMN2 (0.48) NPC1RAB9ASMN1; SMN2POLBHDAC1
SCHEMBL2930928 0.83 NPC1 (0.53) NPC1RAB9ASMN1; SMN2CTSACTSB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1846424-B1 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON INC (US) 2010-01-27 EP claimed
US-7468383-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2008-12-23 US claimed
US-20060189806-A1 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2006-08-24 US claimed
US-8283367-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2012-10-09 US disclosed
EP-1846424-B1 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON INC (US) 2010-01-27 EP disclosed
US-20090075936-A1 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2009-03-19 US disclosed
US-7468383-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2008-12-23 US disclosed
US-20060189806-A1 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2006-08-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060189806-A1 Proteasome inhibitors and methods of using the same PSMB11, PSMB5, PSMB6 NPC1 2169/4885RAB9A 3665/4885SMN1; SMN2 1069/4885
US-20090075936-A1 Proteasome inhibitors and methods of using the same PSMB11, PSMB5, PSMB6 NPC1 2169/4885RAB9A 3665/4885SMN1; SMN2 1069/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.